## SUPPLEMENTARY FIGURES



Supplementary Figure S1: C4 CAR expression is FR $\alpha$ -specific and time-dependent / Expression and viability of CAR-transfected human T cells depend on the concentration of input RNA. A–C. CAR expression as measured by mean fluorescence intensity (MFI) at different times after electroporation with 10 µg C4-27z or C4opt-27z. Specificity for FR $\alpha$ -specific CARs was confirmed in different T cell populations using biotinylated, recombinant human  $\alpha$ -folate protein. D–E. CAR expression is dependent on the concentration of RNA used for electroporation. F–G. Viability (24–72 hr) is inversely proportional to RNA concentration. H–I High concentrations of CAR RNA do not produce irreversible toxicity in T cells as viable cells replace those damaged by electroporation.



Supplementary Figure S2: C4-27z and C4opt-27z CAR T cell expression rapidly declines after FR $\alpha$ -specific antigen encounter in both CD4<sup>+</sup> and CD8<sup>+</sup> T cell populations. Expression of C4-27z and C4opt-27z, but not CD19-27z (control CAR) decline rapidly (measured at 72 hr) after 24 hr co-incubation with FR $\alpha$ <sup>+</sup> SKOV3 tumor on day 1.



Supplementary Figure S3: Limited Th-2 cytokines are secreted by electroporated C4-27z and C4opt-27z RNA CAR T cells in response to FRa<sup>+</sup> tumor cells. A–B, D–E. Antigen-specific IL-4 & IL-10 production by FRa-specific RNA CAR-transfected T cells ~ 24 hr after coculture with the indicated tumor lines at a 1:1 ratio, measured with cytokine bead array. C, F. CD19-27z CAR-T cells were used as negative controls. Results are expressed as a mean +/– SEM of triplicate wells from 1 of at least 2 separate experiments.







Supplementary Figure S5: Th-1 cytokines are secreted by both CD4<sup>+</sup> and CD8<sup>+</sup> C4-27z and C4opt-27z RNA CAR T cells in response to FR $\alpha^+$  tumor cells. A–B, D–E, G–H, J–K. Antigen-specific IFN- $\gamma$  & IL-2 cytokine production by FR $\alpha$ -specific C4-27z and C4opt-27z RNA CAR-transfected T cells ~ 24 hr after coculture with the indicated tumor lines at a 1:1 ratio, measured with Elisa. C, F, I, L. CD19-27z CAR-T cells were used as negative controls. Results are expressed as a mean +/– SEM of triplicate wells from a single donor.

## **Oncotarget, Supplementary Materials 2015**



Supplementary Figure S6: FR-specific and non-specific CAR T cell killing depends on the concentration of input RNA. A–B FR $\alpha$ -specific lytic function of C4opt-27z CAR T lymphocytes and unrelated lysis by CD19-27z CAR T cells was determined using successively higher RNA concentrations. Both FR $\alpha$ -specific killing by C4opt-27z and non-specific killing by CD19-27z CAR T cells was dependent on the concentration of input RNA. C–D. Cytolysis of C4opt-27z and CD19-27z CAR T cells that were electroporated with escalating doses of RNA was measured after coculture overnight with FR $\alpha$ <sup>-</sup> C30 tumor. Higher RNA concentrations resulted in significant off-target lysis, suggesting lower RNA concentrations may minimize such effects.



**Supplementary Figure S7: CD4<sup>+</sup> and CD8<sup>+</sup> CAR-transfected, FRα-specific T cells show differing lytic function in a bioluminescent killing assay.** A–B. CD4<sup>+</sup> and CD8<sup>+</sup> electroporated C4-27z and C4opt-27z CAR T cells display FRα-specific lytic function, though to differing extents, and similar levels of non-specific lysis C–D.



**Supplementary Figure S8: Dosing Schedules. A.**  $10^7 \times 10^7 \times 10^7 \text{ CAR T}$  cells every 3 days intraperitoneal tumor / treatment model. **B.**  $2 \times 10^7 \times 10^7 \times 10^7 \times 10^7$  weekly intraperitoneal tumor / treatment model. **C.**  $2 \times 10^7 \times 10^7 \times 10^7 \times 10^7$  weekly solid tumor / intratumoral treatment model.



**Supplementary Figure S9: Optimization of C4-27z CAR results in greater RNA production at lower cost.** Removal of open-reading frames (ORFs) and codon optimization of C4-27z CAR resulted in the creation of C4opt-27z CAR, a higher yield **A.** and lower cost **B.** DNA construct.